Wall Street Journal OPINION | COMMENTARY
Follow Your Nose to Herd Immunity
The biology behind ‘breakthrough’ cases and the confusing CDC mask guidance.
By Michael Segal
Aug. 16, 2021 1:04 pm ET
The Centers for Disease Control and Prevention’s latest Covid guidelines have many Americans confused. Vaccinated people are supposed to resume wearing masks, lest they contract and spread the virus. Yet unvaccinated people are still strongly urged to get the shots, which are said to be highly effective. How can both these claims be true?
The answer is that there’s more than one kind of immunity. Internal immunity protects the inside of the body, including the lungs. This occurs by release of antibodies of the Immunoglobulin G type, or IgG, into the blood and production of T-cells. Vaccines injected into our muscles are highly effective at stimulating internal immunity. This largely protects vaccinated people from being overwhelmed by the coronavirus, unless they have an immunodeficiency or are exposed to an unusually large amount of the virus. Vaccination will dramatically reduce your likelihood of serious illness or death if you’re exposed to SARS-CoV-2.
In contrast, mucosal immunity provides the first line of defense by protecting the nose and mouth, and by doing so also reduces spread to others. The mucous membranes secrete a particular form of antibodies of the Immunoglobulin A type, or IgA. But vaccines injected into our muscles—including all the approved inoculations against Covid—are largely ineffective at stimulating the secretion of IgA into our noses that occurs after actual infection with a virus. As a result, vaccinated people can contract a Covid-19 infection confined to the mucous membranes. They may get the sniffles but can spread the virus to others even if they are asymptomatic. That’s why it makes sense for them to wear a mask under some circumstances.
All this has implications for public-health authorities’ determination to achieve herd immunity through vaccination alone. In the Provincetown, Mass., outbreak, which informed the CDC’s recent change in guidelines, viral loads in the nose were “similarly high” in the vaccinated and unvaccinated, suggesting that the vaccine’s efficacy against infection in the nose had fallen to zero with the advent of the Delta variant. That would mean herd immunity through vaccination is impossible.
But this data appears to be distorted by ascertainment bias: The vaccinated people who showed up for testing were disproportionately those who were symptomatic. Better-controlled data from the Mayo Clinic suggests that efficacy of the vaccines against nasal infection, including asymptomatic cases, has fallen from the original level of around 90% to 76% for the Moderna vaccine and 42% for the Pfizer vaccine since Delta’s emergence. It follows that herd immunity from intramuscular vaccination is still possible, but it would require either a higher level of vaccination or continued masking and social distancing.
Vaccines administered via nasal spray exist for other ailments, including polio. They’re under development for Covid-19 to supplement existing shots with mucosal immunity. In the meantime, herd immunity may prove difficult to achieve unless more people get infected and develop natural immunity of both types. Given the dangers of infection, officials are rightly reluctant to encourage actual infection, and loath to mention its benefit in conferring mucosal immunity.
But we shouldn’t shun people who have recovered from Covid. Vaccine mandates for in-person interactions—whether imposed by governments, employers or businesses—should make exceptions for the previously infected, who thanks to natural mucosal immunity are likely at less risk than never-infected vaccinated people of spreading the virus to others.
Dr. Segal is a neurologist and neuroscientist.
Appeared in the August 17, 2021, print edition as 'Follow Your Nose to Herd Immunity'.
https://www.wsj.com/articles/covid-19-herd-provincetown-mayo-delta-mask-mandate-vaccine-passport-cdc-mucosal-immunity-11629128219
Copyright ©2021 Michael Segal
The WSJ printed a letter in response from Michael Raab MD suggesting to vaccinated people that they develop mucosal immunity by not wearing masks and thereby getting infected and developing mucosal immunity. There are problems with this suggestion:
- Going maskless would result in infection with the Delta variant, for which vaccination is only partially effective. The original Wuhan strain is, in comparison to the Delta variant, a live attenuated form of the virus. It would make more sense to develop mucosal immunity from the Wuhan strain than from the Delta variant.
- Going maskless would result in risk of transmitting infection to others. Being infected under controlled isolation, in comparison, would have little such risk.
But don't expect governments to offer controlled infection with the Wuhan strain, even though it makes more sense than going maskless after vaccination. But a more benign coronavirus might be tried as a mucosal vaccine, e.g., one of the coronaviruses causing the common cold, or a genetically attenuated form of the Wuhan strain.
Related articles and resources:
- New York Magazine interview with Harvard epidemiologist Michael Mina.
- 15 February 2021 "Discrete SARS-CoV-2 antibody titers track with functional humoral stability". Note: Despite a dearth of federally-funded studies of natural immunity, hedge-fund leader Nancy Zimmerman and entrepreneur Elon Musk funded researchers at Harvard and MIT to do such studies.
- 26 July 2021 Lavelle EC, Ward RW "Mucosal vaccines — fortifying the frontiers" Nature Reviews Immunology 22: 236–250
- Boston Globe article "Could a spritz in the nose stop COVID’s spread?" 26 August 2021
- Stat article "Inside Pfizer’s labs, ‘variant hunters’ race to stay ahead of the pandemic’s next twist" 30 August 2021. Note: "Monitoring the virus so closely has yielded some surprises, including calling into question old assumptions about vaccines: Recipients have protection before the vaccines have generated a significant antibody response, for example, a finding that is leading researchers to devise new methods of evaluating future vaccine candidates.
There doesn’t seem to be a linear correlation between the number of antibodies and level of protection. Studying Covid-19 has only emphasized how little we know. “A lot of times, when you’re working in this field, you’d look at the animal data and say this thing has a wimpy antibody response, let’s not go ahead with it,” said [Vidia] Roopchand [principal scientist for viral vaccines at Pfizer]. Data from the Phase 3 efficacy study of the Covid vaccine undermines that approach: Vaccinated participants have protections against the virus by day 12, at a time when there’s barely any antibody response. “That was the biggest surprise,” said Roopchand."
- Gazit S et al. (25 August 2021 preprint) "Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections". Note: "SARS-CoV-2-naïve vaccinees had a 13.06-fold ... increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant (P<0.001) for symptomatic disease as well. When allowing the infection to occur at any time before vaccination (from March 2020 to February 2021), evidence of waning natural immunity was demonstrated, though SARS-CoV-2 naïve vaccinees had a 5.96-fold ... increased risk for breakthrough infection and a 7.13-fold ... increased risk for symptomatic disease. SARS-CoV-2-naïve vaccinees were also at a greater risk for COVID-19-related-hospitalizations compared to those that were previously infected."
- 26 August 2021 Science analysis "Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital".
- Krause PR et al. "Considerations in boosting COVID-19 vaccine immune responses" Lancet 13 September 2021
- "Our Most Reliable Pandemic Number Is Losing Meaning: A new study suggests that almost half of those hospitalized with COVID-19 have mild or asymptomatic cases". The Atlantic, 13 September 2021.
- "Covid Confusion at the CDC
" by Marty Makary, Wall Street Journal, 14 September print edition.
- 12 October 2021 New York Times article "If You’ve Had Covid, Do You Need the Vaccine?". Note: Hidden behind the simple title is 2 questions: do you need the vaccine to protect yourself, and do you need the vaccine to reduce spreading to others. For yourself, the prudent course of action is to get at least one shot. For spreading to others, it is likely that a person who has recovered but is not vaccinated is less likely to spread to others than a vaccinated person who has not experienced the virus infection. For the legal cases, spreading to others is the criterion that justifies a vaccine requirement, so these cases are weak.
- Sano et al. preprint Efficient mucosal antibody response to SARS-CoV-2 vaccination is induced in previously infected individuals.
- León et al. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021, 19 January 2022 in Morbidity and Mortality Weekly Report (MMWR).
- 3 February 2022 New York Times article "The Covid Vaccine We Need Now May Not Be a Shot
".